Evoke Pharma And EVERSANA Announce Abstract Acceptance At 2023 American Neurogastroenterology And Motility Society Meeting
Portfolio Pulse from Happy Mohamed
Evoke Pharma (NASDAQ:EVOK) and EVERSANA have announced that their abstract on the use of GIMOTI (nasal metoclopramide) in reducing healthcare visits for diabetic gastroparesis patients will be presented at the American Neurogastroenterology and Motility Society (ANMS) Annual Meeting. The study involved 294 patients and found that GIMOTI reduced the need for doctor's office, emergency department, inpatient, and outpatient visits. The announcement coincides with Gastroparesis Awareness Month.

August 07, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evoke Pharma's study on GIMOTI's effectiveness in reducing healthcare visits for diabetic gastroparesis patients is likely to boost the company's reputation and potentially increase demand for GIMOTI.
The positive results from the study on GIMOTI's effectiveness in reducing healthcare visits for diabetic gastroparesis patients is likely to enhance Evoke Pharma's reputation in the market. This could potentially lead to increased demand for GIMOTI, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100